Phase III Study of HRS-5635 in Nucleos(t)Ide Analogue-suppressed HBeAg-negative Patients With Chronic Hepatitis B
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-designed Phase III Clinical Study to Evaluate the Efficacy and Safety of HRS-5635 Injection in Nucleos(t)Ide Analogue-suppressed HBeAg-negative Patients With Chronic Hepatitis B
This study is intended to confirm the efficacy, safety, pharmacokinetic (PK) profile, and immunogenicity of HRS-5635 injection as compared to the placebo arm in nucleos(t)ide analogue-suppressed HBeAg-negative patients with chronic hepatitis B. The total duration of the study, including screening (up to 4 weeks), the double-blind treatment stage (60 weeks),NAs-only treatment stage(12 weeks) and the off-treatment follow-up (24 weeks), is up to approximately 100 weeks at maximum for each participant.
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Fase
Fase
- Fase 3
Contactos y Ubicaciones
Estudio Contacto
Estudio Contacto
- Nombre: Yi Lu
- Número de teléfono: 0518-82342973
- Correo electrónico: minghao.lyu@hengrui.com
Ubicaciones de estudio
-
-
Guangzhou
-
Guangzhou, Guangzhou, Porcelana, 510515
- Reclutamiento
- Nanfang Hospital, Southern Medical University
-
Investigador principal:
- Jinlin Hou
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Chronic hepatitis B defined as HBV infection documented for at least 6 months prior to screening;
- Virologically suppressed on nucleoside or nucleotide analogues treatment with HBV DNA below the lower limit of quantitation;
- HBeAg negative at screening;
- On commercially available NAs monotherapy for at least 24 weeks before randomization, and the dosing regimen remained unchanged for at least 4 weeks before randomization;
- Need to take effective contraceptive measures;
- Volunteer to sign an informed consent.
Exclusion Criteria:
- History of cirrhosis or clinical evidence of hepatic decompensation, confirmed or suspected liver cancer, with other liver diseases other than chronic hepatitis B that may affect the evaluation of the study;
- With autoimmune disease;
- History of solid organ transplantation or hematopoietic stem cell transplantation;
- Clinically significant and unstable or uncontrolled severe cardiovascular and cerebrovascular diseases;
- Malignant tumors were diagnosed within 5 years prior to randomization;
- Major trauma or major surgery within the 12 weeks prior to randomization, or surgical plans or other treatment during the study period which the investigators determined may influence the evaluation of the study results;
- Laboratory tests during the screening period were obviously abnormal;
- Prolonged ECG QTcF or other clinically significant abnormal results that may pose a significant safety risk to the subject during the screening period;
- History of drug use, alcohol or drug abuse in the 12 months prior to randomization;
- Participated in clinical study of other drugs (received experimental drugs);
- Pregnant or nursing women;
- Allergic to a drug ingredient or component;
- Other reasons for ineligibility as judged by the investigators.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Cuadruplicar
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Comparador de placebos: Placebo
|
Placebo, administered by subcutaneous injection. |
|
Experimental: HRS-5635 Injection
|
HRS-5635 Injection, administered by subcutaneous injection; |
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Periodo de tiempo |
|---|---|
|
Percentage of participants with sustained HBV DNA suppression and HBsAg loss within 24 weeks after discontinuation of all HBV therapy
Periodo de tiempo: 24 weeks after discontinuation of all CHB treatment
|
24 weeks after discontinuation of all CHB treatment
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Periodo de tiempo |
|---|---|
|
Percentage of participants with sustained HBV DNA suppression and HBsAg < 100 IU/mL
Periodo de tiempo: Pre-specified time points up to 24 weeks after discontinuation of all CHB treatment
|
Pre-specified time points up to 24 weeks after discontinuation of all CHB treatment
|
|
Percentage of participants with sustained HBV DNA suppression and HBsAg < 10 IU/mL
Periodo de tiempo: Pre-specified time points up to 24 weeks after discontinuation of all CHB treatment
|
Pre-specified time points up to 24 weeks after discontinuation of all CHB treatment
|
|
Percentage of participants with sustained HBV DNA suppression
Periodo de tiempo: Pre-specified time points up to 24 weeks after discontinuation of all CHB treatment
|
Pre-specified time points up to 24 weeks after discontinuation of all CHB treatment
|
|
Percentage of participants with HBsAg < 100 IU/mL
Periodo de tiempo: Pre-specified time points up to 24 weeks after discontinuation of all CHB treatment
|
Pre-specified time points up to 24 weeks after discontinuation of all CHB treatment
|
|
Percentage of participants with HBsAg < 10 IU/mL
Periodo de tiempo: Pre-specified time points up to 24 weeks after discontinuation of all CHB treatment
|
Pre-specified time points up to 24 weeks after discontinuation of all CHB treatment
|
|
Changes from baseline in mean log10 HBsAg levels
Periodo de tiempo: Pre-specified time points up to 24 weeks after discontinuation of all CHB treatment
|
Pre-specified time points up to 24 weeks after discontinuation of all CHB treatment
|
|
Percentage of participants with HBsAg loss
Periodo de tiempo: Pre-specified time points up to 24 weeks after discontinuation of all CHB treatment
|
Pre-specified time points up to 24 weeks after discontinuation of all CHB treatment
|
|
Percentage of participants with HBsAg seroconversion
Periodo de tiempo: Pre-specified time points up to 24 weeks after discontinuation of all CHB treatment
|
Pre-specified time points up to 24 weeks after discontinuation of all CHB treatment
|
|
Percentage of participants with HBeAb positive
Periodo de tiempo: Pre-specified time points up to 24 weeks after discontinuation of all CHB treatment
|
Pre-specified time points up to 24 weeks after discontinuation of all CHB treatment
|
|
Percentage of participants with virologic breakthrough
Periodo de tiempo: Pre-specified time points up to 24 weeks after discontinuation of all CHB treatment
|
Pre-specified time points up to 24 weeks after discontinuation of all CHB treatment
|
|
Percentage of participants with drug resistance
Periodo de tiempo: Pre-specified time points up to 24 weeks after discontinuation of all CHB treatment
|
Pre-specified time points up to 24 weeks after discontinuation of all CHB treatment
|
|
Relapse rate after discontinuation of NAs therapy
Periodo de tiempo: Up to 24 weeks after discontinuation of NAs treatment
|
Up to 24 weeks after discontinuation of NAs treatment
|
|
Treatment-emergent adverse events
Periodo de tiempo: Up to 24 weeks after discontinuation of NAs treatment
|
Up to 24 weeks after discontinuation of NAs treatment
|
|
Percentage of participants with detectable anti-drug antibodies
Periodo de tiempo: Pre-specified time points up to 24 weeks after discontinuation of all CHB treatment
|
Pre-specified time points up to 24 weeks after discontinuation of all CHB treatment
|
|
Percentage of participants who meet the criteria for stopping nucleos(t)ide analogue (NA) therapy
Periodo de tiempo: Week 72 and Week 96
|
Week 72 and Week 96
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Otros números de identificación del estudio
Otros números de identificación del estudio
- HRS-5635-301
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .